Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer

Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer

Item
http://www.wikidata.org/entity/Q34019159
ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsOverall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung CancerAssociation between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung CancerClinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
P2860

Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer

Item
http://www.wikidata.org/entity/Q34019159
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@ast
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@nl
type
label
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@ast
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@nl
prefLabel
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@ast
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
P2093
P2860
P304
P31
P356
10.1016/J.CLLC.2013.06.005
P407
P433
P478
P577
P698
P921
P932